{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:46:50Z","timestamp":1766400410950,"version":"3.40.5"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.vaccine.2016.12.036","type":"journal-article","created":{"date-parts":[[2017,1,5]],"date-time":"2017-01-05T22:17:56Z","timestamp":1483654676000},"page":"821-830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["A novel vaccinological evaluation of intranasal vaccine and adjuvant safety for preclinical tests"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3384-7414","authenticated-orcid":false,"given":"Eita","family":"Sasaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madoka","family":"Kuramitsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruka","family":"Momose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouji","family":"Kobiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiki","family":"Aoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken J.","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuo","family":"Mizukami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Hamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.12.036_b0005","first-page":"213","article-title":"Comparison of adverse reactions to whole-virion and split-virion influenza vaccines in hospital personnel","volume":"145","author":"al-Mazrou","year":"1991","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.vaccine.2016.12.036_b0010","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1586\/14760584.2.2.285","article-title":"Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines","volume":"2","author":"Peppoloni","year":"2003","journal-title":"Exp Rev Vacc"},{"key":"10.1016\/j.vaccine.2016.12.036_b0015","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa030595","article-title":"Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland","volume":"350","author":"Mutsch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.12.036_b0020","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0016-5085(99)70063-6","article-title":"Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults","volume":"16","author":"Michetti","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.vaccine.2016.12.036_b0025","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1586\/14760584.3.6.643","article-title":"Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine","volume":"6","author":"Belshe","year":"2004","journal-title":"Exp Rev Vacc"},{"key":"10.1016\/j.vaccine.2016.12.036_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.0300-9475.2004.01382.x","article-title":"Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines","volume":"59","author":"Cox","year":"2004","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.vaccine.2016.12.036_b0035","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1128\/jcm.8.4.431-434.1978","article-title":"Comparison of immunogenicity of a whole virion and a subunit influenza vaccine in adults","volume":"8","author":"Ortbals","year":"1978","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2016.12.036_b0040","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejpb.2015.05.023","article-title":"Current and next generation influenza vaccines: formulation and production strategies","volume":"94","author":"Soema","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.vaccine.2016.12.036_b0045","first-page":"S45","article-title":"Safety evaluation of vaccine adjuvants. National cooperative vaccine development working group","volume":"9","author":"Goldenthal","year":"1993","journal-title":"AIDS Res Hum Retrovirus"},{"key":"10.1016\/j.vaccine.2016.12.036_b0050","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.0818-9641.2004.01272.x","article-title":"Vaccine adjuvants: current state and future trends","volume":"82","author":"Petrovsky","year":"2004","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2016.12.036_b0055","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev.iy.04.040186.002101","article-title":"Current status of immunological adjuvants","volume":"4","author":"Warren","year":"1986","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2016.12.036_b0060","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1089\/aid.1992.8.1409","article-title":"An update on vaccine adjuvants in clinical trial","volume":"8","author":"Edelman","year":"1992","journal-title":"AIDS Res Hum Retrovirus"},{"key":"10.1016\/j.vaccine.2016.12.036_b0065","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0161-5890(91)90074-T","article-title":"Immunological adjuvants: desirable properties and side-effects","volume":"28","author":"Allison","year":"1991","journal-title":"Mol Immunol"},{"key":"10.1016\/j.vaccine.2016.12.036_b0070","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1128\/IAI.51.3.816-825.1986","article-title":"Uveitis induction in the rabbit by muramyl dipeptides","volume":"51","author":"Waters","year":"1986","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.12.036_b0075","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1016\/S0264-410X(03)00078-1","article-title":"Roles of anti-hemagglutinin IgA and IgG antibodies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza pneumonia","volume":"21","author":"Ito","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.036_b0080","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0264-410X(90)90250-P","article-title":"Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza","volume":"8","author":"Tamura","year":"1990","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.036_b0085","unstructured":"National Institute of Infectious Diseases, Japan. Minimum requirements for biological products; 2006. <http:\/\/www.nih.go.jp\/niid\/en\/mrbp-e.html>."},{"key":"10.1016\/j.vaccine.2016.12.036_b0090","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.biologicals.2008.07.007","article-title":"An improved abnormal toxicity test by using reference vaccine-specific body weight curves and histopathological data for monitoring vaccine quality and safety in Japan","volume":"37","author":"Mizukami","year":"2009","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2016.12.036_b0095","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/j.vaccine.2008.02.031","article-title":"Application of DNA microarray technology to influenza A\/Vietnam\/1194\/2004 (H5N1) vaccine safety evaluation","volume":"26","author":"Mizukami","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.036_b0100","doi-asserted-by":"crossref","first-page":"e101835","DOI":"10.1371\/journal.pone.0101835","article-title":"System vaccinology for the evaluation of influenza vaccine safety by multiplex gene detection of novel biomarkers in a preclinical study and batch release test","volume":"9","author":"Mizukami","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.12.036_b0105","doi-asserted-by":"crossref","first-page":"e0124392","DOI":"10.1371\/journal.pone.0124392","article-title":"Establishment of a new quality control and vaccine safety test for influenza vaccines and adjuvants using gene expression profiling","volume":"10","author":"Momose","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.12.036_b0110","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1073\/pnas.1319268111","article-title":"Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist","volume":"111","author":"Kobiyama","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2016.12.036_b0115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4161\/hv.1.1.1553","article-title":"Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adults","volume":"1","author":"Halperin","year":"2005","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2016.12.036_b0120","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.vaccine.2006.05.130","article-title":"Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994 to 2004","volume":"25","author":"Nakayama","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.036_b0125","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1016\/j.vaccine.2008.06.086","article-title":"Application of quantitative gene expression analysis for pertussis vaccine safety control","volume":"26","author":"Hamaguchi","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.036_b0130","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1016\/j.vaccine.2006.12.059","article-title":"Two vaccine toxicity-related genes Agp and Hpx could prove useful for pertussis vaccine safety control","volume":"25","author":"Hamaguchi","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.036_b0135","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7883\/yoken.63.25","article-title":"Induction of indistinguishable gene expression patterns in rats by Vero cell-derived and Mouse brain-derived Japanese Encephalitis vaccines","volume":"63","author":"Momose","year":"2010","journal-title":"Jpn J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.12.036_b0140","series-title":"Immunological adjuvants and vaccines","first-page":"213","article-title":"Recommendations for the assessment of adjuvants","author":"Stewart-Tull","year":"1989"},{"key":"10.1016\/j.vaccine.2016.12.036_b0145","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/223715a0","article-title":"Toxic properties of a synthetic double-stranded RNA. Endotoxin-like properties of poly I. Poly C, an interferon stimulator","volume":"5207","author":"Absher","year":"1969","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2016.12.036_b0150","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/jnci\/57.3.599","article-title":"A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patients with leukemia or solid tumors","volume":"57","author":"Robinson","year":"1976","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2016.12.036_b0155","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.it.2010.11.004","article-title":"Inflammasomes as mediators of immunity against influenza virus","volume":"32","author":"Pang","year":"2011","journal-title":"Trends Immunol"},{"key":"10.1016\/j.vaccine.2016.12.036_b0160","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/j.vaccine.2013.02.016","article-title":"Influenza A whole virion vaccine induces a rapid reduction of peripheral blood leukocytes via interferon-\u03b1-dependent apoptosis","volume":"31","author":"Ato","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.036_b0165","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/infdis\/jiq156","article-title":"Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans","volume":"203","author":"Bucasas","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.12.036_b0170","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1038\/ncomms4864","article-title":"Pathogenic potential of interferon \u03b1\u03b2 in acute influenza infection","volume":"5","author":"Davidson","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2016.12.036_b0175","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1016\/j.vaccine.2010.01.060","article-title":"A whole genome transcriptional analysis of the early immune response induced by live attenuated and inactivated influenza vaccines in young children","volume":"28","author":"Zhu","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.036_b0180","doi-asserted-by":"crossref","first-page":"e00299","DOI":"10.7554\/eLife.00299","article-title":"Integrative genomic analysis of the human immune response to influenza vaccination","volume":"2","author":"Franco","year":"2013","journal-title":"Elife"},{"key":"10.1016\/j.vaccine.2016.12.036_b0185","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1086\/599790","article-title":"Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older","volume":"200","author":"Falsey","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.12.036_b0190","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.4049\/jimmunol.165.9.4778","article-title":"Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues","volume":"165","author":"van Ginkel","year":"1999","journal-title":"J Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16312610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16312610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T20:24:52Z","timestamp":1658348692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16312610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0264410X16312610"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.12.036","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel vaccinological evaluation of intranasal vaccine and adjuvant safety for preclinical tests","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.12.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}